A crossover comparison of patient satisfaction with two teriparatide regimens: primary results of the Japanese Osteoporosis Intervention Trial 06 (JOINT-06).

Soen S, Uemura Y, Tanaka S, Takeuchi Y, Endo N, Takada J, Ikeda S, Iwamoto J, Okimoto N, Tanaka S

Journal of bone and mineral metabolism11 Jun 2024Cited by 3 (Europe PMC)

PMID38861178PMCIDPMC11455704DOI10.1007/s00774-024-01521-7PepBankPUB-38861178

Summary

IntroductionThis study aimed to compare treatment satisfaction with two dosing regimens (two teriparatide [TPTD] self-injection systems) in osteoporosis patients at high risk of fracture.Materials and methodsIn this open-label crossover randomized trial comparing self-injected once-daily (1/D)-TPTD with self-injected twice-weekly (2/W)-TPTD, three satisfaction variables were evaluated by questionnaire for 2 years. The primary endpoint was overall satisfaction and secondary endpoints were satisfaction with treatment effectiveness and with utility of the self-injection device. Changes in quality of life (QOL) assessed by EuroQol-5 Dimension, pain assessed by visual analogue scale (VAS), and anthropometric parameters were also analyzed. Safety was evaluated based on the incidence and severity of adverse events (AEs).ResultsThe 1/D-TPTD and 2/W-TPTD groups consisted of 180 (75.9 ± 7.3 years) and 179 (age: 75.5 ± 6.9 years) patients, respectively. After 26 weeks of treatment, no significant between-group difference in the persistence rate (79.4% vs 72.6% in the 1/D-TPTD and 2/W-TPTD groups, respectively), distributions of overall satisfaction scores, and satisfaction with treatment (p > 0.05) were observed. However, several items of satisfaction with the utility of the injection device were significantly higher in the 2/W-TPTD group (p < 0.05). Statistical improvements from baseline values were observed in QOL and pain VAS in both groups (p < 0.05). No serious AEs were reported.ConclusionThe between-group similarity of overall treatment satisfaction and effectiveness scores and between-group difference in satisfaction with the utility of the self-injection device was useful information for real-world treatment of osteoporosis. Both medication regimens were well tolerated.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study7

3 results from studies that gave the peptide. 3 results from people.

01HumanRandomized controlled trialEfficacy outcome
In osteoporosis patients, quality of life improved from baseline in both teriparatide regimen groups.
In plain wordsIn osteoporosis patients, quality of life improved from baseline in both teriparatide regimen groups.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseQuality of life
Study
n = 359
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated
Source sentences
Summary
Statistical improvements from baseline values were observed in QOL and pain VAS in both groups (p < 0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
In this open-label crossover randomized trial comparing self-injected once-daily (1/D)-TPTD with self-injected twice-weekly (2/W)-TPTD, three satisfaction variables were evaluated by questionnaire for 2 years.
Summary · context
The 1/D-TPTD and 2/W-TPTD groups consisted of 180 (75.9 ± 7.3 years) and 179 (age: 75.5 ± 6.9 years) patients, respectively.
Show in the study text Report a problemFND-3886117805
02HumanRandomized controlled trialEfficacy outcome
In osteoporosis patients, pain VAS improved from baseline in both teriparatide regimen groups.
In plain wordsIn osteoporosis patients, pain improved from baseline in both teriparatide regimen groups.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreasePain VAS
Study
n = 359
Comparator
Baseline
Outcome group
Pain · Musculoskeletal
Studied dose
Dose not stated
Source sentences
Summary
Statistical improvements from baseline values were observed in QOL and pain VAS in both groups (p < 0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
In this open-label crossover randomized trial comparing self-injected once-daily (1/D)-TPTD with self-injected twice-weekly (2/W)-TPTD, three satisfaction variables were evaluated by questionnaire for 2 years.
Summary · context
The 1/D-TPTD and 2/W-TPTD groups consisted of 180 (75.9 ± 7.3 years) and 179 (age: 75.5 ± 6.9 years) patients, respectively.
Show in the study text Report a problemFND-3886117806
03HumanRandomized controlled trialSafety outcome
In osteoporosis patients receiving either teriparatide regimen, no serious adverse events were reported.
In plain wordsIn osteoporosis patients receiving either teriparatide regimen, no serious adverse events were reported.
Peptide
Teriparatide (PTH 1-34)
Outcome
Not applicableSerious adverse events
Study
n = 359
Outcome group
Adverse events · Whole body
Studied dose
Dose not stated
Source sentences
Summary
No serious AEs were reported.
2 context sentences(design, population, supporting numbers)
Summary · context
In this open-label crossover randomized trial comparing self-injected once-daily (1/D)-TPTD with self-injected twice-weekly (2/W)-TPTD, three satisfaction variables were evaluated by questionnaire for 2 years.
Summary · context
The 1/D-TPTD and 2/W-TPTD groups consisted of 180 (75.9 ± 7.3 years) and 179 (age: 75.5 ± 6.9 years) patients, respectively.
Show in the study text Report a problemFND-3886117807

Studies that did not test the peptide alone4

In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Teriparatide (PTH 1-34).

04HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome
In osteoporosis patients, overall satisfaction scores did not differ between daily and twice-weekly teriparatide at 26 weeks.
In plain wordsIn osteoporosis patients, overall satisfaction did not differ between daily and twice-weekly teriparatide.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeOverall satisfaction
Study
n = 359
Comparator
Twice-weekly teriparatide
Analysis
Primary
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
After 26 weeks of treatment, no significant between-group difference in the persistence rate (79.4% vs 72.6% in the 1/D-TPTD and 2/W-TPTD groups, respectively), distributions of overall satisfaction scores, and satisfaction with treatment (p > 0.05) were observed.
2 context sentences(design, population, supporting numbers)
Summary · context
The primary endpoint was overall satisfaction and secondary endpoints were satisfaction with treatment effectiveness and with utility of the self-injection device.
Summary · context
In this open-label crossover randomized trial comparing self-injected once-daily (1/D)-TPTD with self-injected twice-weekly (2/W)-TPTD, three satisfaction variables were evaluated by questionnaire for 2 years.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Show in the study text Report a problemFND-3886117802
05HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome
In osteoporosis patients, several injection-device utility satisfaction items were higher with twice-weekly than daily teriparatide.
In plain wordsIn osteoporosis patients, several device utility satisfaction scores were higher with twice-weekly than daily teriparatide.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseInjection device utility satisfaction
Study
n = 359
Comparator
Daily teriparatide
Analysis
Secondary
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
However, several items of satisfaction with the utility of the injection device were significantly higher in the 2/W-TPTD group (p < 0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
In this open-label crossover randomized trial comparing self-injected once-daily (1/D)-TPTD with self-injected twice-weekly (2/W)-TPTD, three satisfaction variables were evaluated by questionnaire for 2 years.
Summary · context
The 1/D-TPTD and 2/W-TPTD groups consisted of 180 (75.9 ± 7.3 years) and 179 (age: 75.5 ± 6.9 years) patients, respectively.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Show in the study text Report a problemFND-3886117804
06HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome
In osteoporosis patients, persistence did not differ between daily and twice-weekly teriparatide at 26 weeks.
In plain wordsIn osteoporosis patients, persistence did not differ between daily and twice-weekly teriparatide.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changePersistence
Study
n = 359
Comparator
Twice-weekly teriparatide
Outcome group
Bone and joint · Musculoskeletal
Measurements
Persistence
79.4%
daily
Persistence
72.6%
twice-weekly
Source sentences
Summary
After 26 weeks of treatment, no significant between-group difference in the persistence rate (79.4% vs 72.6% in the 1/D-TPTD and 2/W-TPTD groups, respectively), distributions of overall satisfaction scores, and satisfaction with treatment (p > 0.05) were observed.
2 context sentences(design, population, supporting numbers)
Summary · context
In this open-label crossover randomized trial comparing self-injected once-daily (1/D)-TPTD with self-injected twice-weekly (2/W)-TPTD, three satisfaction variables were evaluated by questionnaire for 2 years.
Summary · context
The 1/D-TPTD and 2/W-TPTD groups consisted of 180 (75.9 ± 7.3 years) and 179 (age: 75.5 ± 6.9 years) patients, respectively.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Show in the study text Report a problemFND-3886117801
07HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome
In osteoporosis patients, persistence rate (79.4% vs 72.6% with once-daily vs twice-weekly) and satisfaction scores did not differ significantly between the two teriparatide regimens at 26 weeks.
In plain wordsIn osteoporosis patients, persistence and satisfaction scores did not differ significantly between daily and twice-weekly teriparatide.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changePersistence rate and treatment satisfaction
Study
n = 359
Comparator
Twice-weekly teriparatide
Outcome group
Bone and joint · Musculoskeletal
Measurements
Persistence rate
79.4%
1/D-TPTD group
Persistence rate
72.6%
2/W-TPTD group
Source sentences
Summary
After 26 weeks of treatment, no significant between-group difference in the persistence rate (79.4% vs 72.6% in the 1/D-TPTD and 2/W-TPTD groups, respectively), distributions of overall satisfaction scores, and satisfaction with treatment (p > 0.05) were observed.
2 context sentences(design, population, supporting numbers)
Summary · context
In this open-label crossover randomized trial comparing self-injected once-daily (1/D)-TPTD with self-injected twice-weekly (2/W)-TPTD, three satisfaction variables were evaluated by questionnaire for 2 years.
Summary · context
The 1/D-TPTD and 2/W-TPTD groups consisted of 180 (75.9 ± 7.3 years) and 179 (age: 75.5 ± 6.9 years) patients, respectively.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Show in the study text Report a problemFND-3886117803

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.